Navigation Links
Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
Date:1/8/2008

ctor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 percent to 50 percent of the estimated 50,000 identified PKU patients in the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of market exclusivity in the United States. In November 2007, Merck Serono submitted a Marketing Authorization Application (MAA) to the EMEA for sapropterin dihydrochloride as an oral treatment for patients suffering from HPA due to PKU or BH4 deficiency. If approved in the EU, it will receive 10 years of market exclusivity for this indication.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. To learn more about PKU, please visit http://www.PKU.com.

About Fairview Specialty Pharmacy

Fairview Specialty Pharmacy provides personal medication management services to patients who take high-cost or self-injected drugs for chronic conditions. Fairview Specialty Pharmacy ensures that patients receive their medications safely and on time via services including medication management and monitoring, free shipping anywhere in the US, and monthly refill reminder phone calls. All calls are answered by "live" pha
'/>"/>

SOURCE Fairview Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Specialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.
2. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
3. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
4. Albemarle Raises Prices of Specialty Aluminas
5. Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise
6. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
7. Survey shows gender differences are factor when surgeons in training choose a subspecialty
8. Packard Childrens Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home
9. Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma
10. Mylan Announces Management of Specialty Business, Dey L.P.
11. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Skincare Industry Newcomer Shines 51058 1Skincare Industry Newcomer Shines 51058 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 1For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 3Allied World Schedules Second Quarter 2009 Earnings Announcement and Conference Call 51052 1